NeoGenomics Q3 2023 Sales $151.95M Beat $142.00M Estimate
Portfolio Pulse from vinayak@benzinga.com
NeoGenomics reported Q3 2023 sales of $151.95 million, beating the analyst consensus estimate of $142.00 million by 7.01 percent. This represents a 17.99 percent increase over the same period last year.
November 06, 2023 | 10:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NeoGenomics' Q3 2023 sales exceeded analyst estimates by 7.01%, indicating strong performance. This could positively impact the company's stock price.
NeoGenomics' sales for Q3 2023 exceeded analyst estimates, which is typically a positive signal for investors and can lead to an increase in the stock price. The 17.99% YoY increase further strengthens this positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100